notablelabs.com - NTBL EV/Sales Multiple

Public company logo of Notable Labs Ltd (NTBL)

Notable Labs, Ltd. (NTBL) supports ESG goals by optimizing medication consumption through precise therapy selection. The business model relies on external synthesis and testing, creating a strong dependency on contractors. This niche IT platform is subject to binary risks. The EV/Sales valuation level illustrates the market consensus, while the metric confirms the company's current valuation relative to its revenue.

Notable Labs Corp (NTBL) - Enterprise Value-to-Revenue Ratio from 07/04/2022 to 11/20/2026

Financial and market metric breakdowns for Notable Labs Inc. (NTBL)

- stock price and consensus target price:
Initial company analysis:Notable Labs, Ltd. - NTBL
Core merchandise of Notable Labs Ltd

The assessment of Notable Labs, Ltd. (NTBL) resilience to market shocks depends on the balance between capitalization and revenue, which is critical for an R&D platform specializing in oncology screening automation. Analyzing the EV/Sales multiple, which combines market value and net debt, allows for the identification of asset overvaluation relative to the industry, where a prolonged elevated metric signals a risk of sharp price correction.

Competitor analysis for Notable Labs, Ltd.

Enterprise Value-to-Sales Ratio BeiGene Ltd (ONC)|Halozyme Corp (HALO) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Revolution Medicines Inc (RVMD)|Enterprise Value-to-Revenue Ratio Ascentage Pharma Group|Company Value to Revenue Ratio CGON (CG Oncology Corp)|Enterprise Value-to-Revenue Ratio UroGen Pharma (URGN)|EV/Sales Multiple Bicara Therapeutics (BCAX)|EV/Sales Multiple PSNL (personalis.com)|Business Value to Revenue ERAS|DCTH: Company Value to Revenue|YmAbs - Enterprise Value-to-Revenue Coefficient|aurabiosciences.com (AURA) - Enterprise Value-to-Revenue Ratio|Candel Therapeutics Inc. - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Accuray Inc.|Enterprise Value-to-Revenue Multiple SELLAS Life Sciences Group SLS|EV/Sales Multiple ACTU|CTOR - Enterprise Value-to-Revenue Multiple|EV/Sales Multiple HURA (TuHURA Biosciences, Inc.)|Business Value to Revenue TARA|FATE: Company Value to Revenue|WHWK (aadibio.com) - Company Value to Revenue Ratio|TCRX (TScan Therapeutics, Inc.) - Company Value to Revenue|Enterprise Value-to-Revenue Multiple Champions Oncology Corp (CSBR)|XBIT (XBiotech Inc.) - EV/Sales Multiple|CVM (CEL-SCI Corporation) - Enterprise Value-to-Revenue Coefficient|EV/Sales Multiple OSTX|EV/Sales Multiple Radiopharm Theranostics Ltd (RADX)|EV/Sales Multiple ARTV (Artiva Biotherapeutics)|EV/Sales Multiple Adlai Nortye Ltd. ANL|Veru Inc - EV/Sales Multiple|Total Company Value-to-Revenue Ratio Tempest Therapeutics TPST|XLO: EV/Sales Multiple|Enochian BioSciences (RENB) - EV/Sales Multiple|Company Value to Revenue MURA|Kairos Pharma Ltd - Enterprise Value to Sales Volume|EV/Sales Multiple OKUR|CytoMed Therapeutics Limited (GDTC) - Enterprise Value-to-Sales Ratio|EV/Sales Multiple CRIS (Curis, Inc.)|APLM: Company Value to Revenue Ratio|Tharimmune Corporation - EV/Sales Multiple|ADVB: Enterprise Value-to-Revenue Ratio|GNPX: EV/Sales Multiple|CLDI (Calidi Biotherapeutics Inc.) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Sunshine Biopharma, Inc.|EV/Sales Multiple xeneticbio.com|Enterprise Value-to-Revenue Ratio Salarius (SLRX)|Company Value to Revenue Purple Biotech PPBT|Enterprise Value-to-Revenue Ratio American Oncology Network, Inc. AONC|BeiGene, Ltd. (BGNE) - Enterprise Value-to-Revenue Multiple|Checkpoint Therapeutics Inc. - EV/Sales Multiple|Business Value to Revenue ELEV (Elevation Oncology)|ICAD (iCAD Corp) - Company Value to Revenue|Ikena Oncology, Inc. - Business Value to Revenue|Enterprise Value-to-Revenue Ratio viracta.com|MOR: Business Value to Revenue|EV/Sales Multiple NAYA|Ascentage Pharma - Company Value to Revenue Ratio